| Authors: |
Freedland SJ; 1Department of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA.; 2Section of Urology, Durham VA Medical Center, Durham, NC., Aronson W; 3Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA.; 4Veterans Administration Medical Center, Greater Los Angeles Healthcare System, Los Angeles, CA., Asher A; 5Department of Medicine and Physical Medicine and Rehabilitation and Patient and Family Support Program, Cedars-Sinai Cancer, Los Angeles, CA., Golant M; 6Cancer Support Community, Washington, DC., Lemke E; 7Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI., Morgans AK; 8Dana-Farber Cancer Institute, Boston, MA., Morris D; 9Urology Associates, P.C., Nashville, TN., Sullivan C; 10Harvard Medical School, Massachusetts General Hospital, Boston, MA., Sutton J; 11Carolina Urologic Research Center, Myrtle Beach, SC., Thomson CA; 12Mel & Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ., Twardowski P; 13Department of Urologic Oncology, Saint John's Cancer Institute, Santa Monica, CA., Wefel JS; 14Department of Neuro-Oncology and Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Winters-Stone K; 15Division of Oncological Sciences, Oregon Health & Science University, Portland, OR.; 16Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Chakoian M; 17Us TOO in Seattle, Prostate Cancer Support, Education, and Advocacy, Seattle, WA., Wells T; 18IQVIA, New York, NY., ElSouda D; 19Astellas Pharma Inc., Northbrook, IL., Turnbull J; 18IQVIA, New York, NY., Buzaglo J; 18IQVIA, New York, NY., Mobley C; 18IQVIA, New York, NY., Ivanova J; 20Pfizer Inc., New York, NY., Cohen J; 19Astellas Pharma Inc., Northbrook, IL., Hogue S; 21Aesara, Chapel Hill, NC., El-Chaar N; 19Astellas Pharma Inc., Northbrook, IL., Touya M; 19Astellas Pharma Inc., Northbrook, IL. |
